The South African Health Products Regulatory Authority (Sahpra) has approved the Sinovac-CoronaVac vaccine for use in South Africa. The Chinese-produced vaccine is a two-dose innoculation recommended for patients 18-years and older, with 51% efficacy against the coronavirus. Now that Sahpra approved an additional vaccine to choose from in the country’s inoculation drive, health experts are hopeful it would be able to slow down the spread of the virus. South Africa is experiencing its third wave, spurred by the Delta variant.
Guest: Dr. Boitumelo Semete – CEO, South African Health Products Regulatory Authority
More Posts for Show: NRA